B of A Securities Rates Liquidia (LQDA) hold, $79 Price Target
B of A Securities issued a 'hold' rating for Liquidia, setting a $79 price target, a 3.84% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B of A Securities rated Liquidia Corporation ($LQDA) "hold" with a $79 price target on June 29, 2026.
Since the rating, $LQDA is up 5.4% after 1 week, up 15.6% after 1 month and down 54.3% to date (from the $75.12 close on Jun 29, 2026).
LQDA
Liquidia Corporation
Key Points
- On June 29, 2026, B of A Securities downgraded Liquidia Corporation to a 'hold' rating with a $79 price target.
- B of A Securities's $79 price target implies 3.84% upside from Liquidia Corporation's ($LQDA) current $76.08 share price.
- Liquidia's shares traded near $78.17 on Monday, with a market cap of $6.95 billion and a P/E ratio of 459.8.
- Recent insider activity includes Stephen Bloch selling 100,000 shares on June 22, while several insiders made small purchases on June 16.
Get $LQDA trade alerts by text
We text you when insiders, Congress or big funds trade $LQDA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Liquidia Corporation alert may contain errors. Disclosures
B of A Securities downgraded Liquidia Corporation (NasdaqCM:LQDA) to a 'hold' rating on June 29, 2026, setting a price target of $79. This change comes as the stock traded near $78.17 on Monday.
B of A Securities vs. the S&P 500
Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Liquidia Corporation
Farallon Capital Management LLC held its position steady with 8,656,038 shares worth about $326.7 million. Similarly, Caligan Partners LP maintained its stake at 8,118,892 shares, valued at approximately $306.4 million. BlackRock, Inc. added 781 shares, bringing its total to 5,489,144 shares, valued at around $207.2 million. Findell Capital Management LLC increased its holdings by 650,663 shares, now owning 3,502,112 shares worth $132.2 million, marking a 22.8% increase. Vanguard Capital Management LLC opened a new position with 2,926,945 shares, valued at roughly $110.5 million.
Liquidia Corporation Stock Up 118.7%
Shares of NasdaqCM:LQDA traded near $78.17 on Monday. Liquidia Corporation has a market cap of about $6.95 billion, with a P/E ratio of 459.8 and a forward P/E of 14.0. The stock's beta is 0.593, indicating lower volatility compared to the market. It has a 52-week range between $11.85 and $79.41. The 50-day moving average is $55.67, while the 200-day moving average is $38.09. Liquidia maintains a current ratio of 2.224 and a quick ratio of 1.983, with a debt-to-equity ratio of 170.221.
$LQDA price target
Liquidia Corporation daily closes and this analyst's $79 target. Not advice.
Recent Earnings
Liquidia Corporation reported revenue of $288.1 million, with a robust growth rate of 41.6%. The company posted an EPS of $0.17, achieving a net margin of 7.7% and a return on equity of 28.2%. The next earnings report is scheduled for August 12, 2026.
Insider Buying and Selling at Liquidia Corporation
On June 22, 2026, Stephen Bloch sold 100,000 shares at an average price of $75.74. Earlier, on June 16, several insiders, including Stephen Bloch, Katherine Rielly-Gauvin, Paul Manning, Joanna Horobin, and David Edward Johnson, each purchased 5,882 shares.
Analysts Set New Price Targets
On June 29, 2026, B of A Securities downgraded Liquidia to a 'hold' rating with a $79 price target. On June 22, BTIG maintained its 'buy' rating with a $109 target. HC Wainwright & Co. and Wells Fargo have also maintained 'buy' ratings with targets at $75 and $62, respectively. The consensus recommendation is 'strong buy' with an average target price of $72.38, based on eight analyst opinions.
About Liquidia Corporation
Liquidia Corporation, based in Morrisville, North Carolina, is a biopharmaceutical company focused on developing, manufacturing, and commercializing products for rare cardiopulmonary diseases. Its key products include YUTREPIA, a dry powder inhalation treatment for pulmonary arterial hypertension, and Remodulin, a treprostinil injection. The company also develops L606, a liposomal formulation in phase III trials. Liquidia employs 216 people and is led by CEO Dr. Roger A. Jeffs.
Bottom Line
B of A Securities' downgrade of Liquidia Corporation to a 'hold' reflects a cautious stance on the company's growth potential. Investors keep a close eye on such analyst ratings as they provide insights into market sentiment. However, it's important to remember that these ratings are based on past data and market conditions, which can change.
Related Filing Alerts
Source: B of A Securities's rating change on $LQDA (Jun 29, 2026). Written by software, not financial advice. How we make alerts